These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7452168)

  • 1. Multi-test screening and the chances of being normal.
    Phillips WR; Thompson DJ
    J Fam Pract; 1980 Dec; 11(7):1095-8. PubMed ID: 7452168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-channel laboratory testing and the unexpected abnormal result: a statistical myth corrected.
    Phillips WR; Thompson DJ
    N Z Med J; 1981 Dec; 94(698):462-4. PubMed ID: 6950296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' anxiety and expectations: how they influence family physicians' decisions to order cancer screening tests.
    Haggerty J; Tudiver F; Brown JB; Herbert C; Ciampi A; Guibert R
    Can Fam Physician; 2005 Dec; 51(12):1658-9. PubMed ID: 16926946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multichannel 18-test panels: are 60% of panels abnormal by chance?
    Desbiens NA; Turney SL; Gani KS
    J Lab Clin Med; 1990 Mar; 115(3):292-7. PubMed ID: 2313161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health fair screening: the clinical utility of the comprehensive metabolic profile.
    Alpert JP; Greiner A; Hall S
    Fam Med; 2004; 36(7):514-9. PubMed ID: 15243834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PSA testing in multiphasic health screening.
    Png JC; Akhtar KJ; Tung KH
    Singapore Med J; 1998 May; 39(5):193-5. PubMed ID: 9713222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests.
    Baker SG; Kramer BS
    J Med Screen; 2008; 15(1):18-22. PubMed ID: 18416950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The determination and interpretation of reference intervals for multichannel serum chemistry tests.
    Mold JW; Aspy CB; Blick KE; Lawler FH
    J Fam Pract; 1998 Mar; 46(3):233-41. PubMed ID: 9519021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity.
    Kirkland D; Aardema M; Henderson L; Müller L
    Mutat Res; 2005 Jul; 584(1-2):1-256. PubMed ID: 15979392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optometric glaucoma referrals--measures of effectiveness and implications for screening strategy.
    Gilchrist J
    Ophthalmic Physiol Opt; 2000 Nov; 20(6):452-63. PubMed ID: 11127125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based estimate of the extent of colorectal cancer screening in Ontario.
    Rabeneck L; Paszat LF
    Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of an insurance company-sponsored multichannel chemistry screening initiative.
    Mold JW; Aspy CB; Lawler FH
    J Fam Pract; 1998 Aug; 47(2):110-7. PubMed ID: 9722798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of water and air caloric responses and their ability to distinguish between patients with normal and impaired ears.
    Zapala DA; Olsholt KF; Lundy LB
    Ear Hear; 2008 Aug; 29(4):585-600. PubMed ID: 18600135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes.
    Kirkland DJ; Henderson L; Marzin D; Müller L; Parry JM; Speit G; Tweats DJ; Williams GM
    Mutat Res; 2005 Dec; 588(2):88-105. PubMed ID: 16326131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The anticitrulline antibody test: unsuitable for screening for rheumatoid arthritis].
    Jacobs JW; Bijlsma JW
    Ned Tijdschr Geneeskd; 2008 Jan; 152(2):69-70. PubMed ID: 18265793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.